nabilone

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
80
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Neuropathic Pain

Conditions

Neuropathic Pain, Multiple Sclerosis

Trial Timeline

Jun 1, 2007 โ†’ Jul 1, 2012

About nabilone

nabilone is a approved stage product being developed by Bausch Health for Neuropathic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00480181. Target conditions include Neuropathic Pain, Multiple Sclerosis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT00480181ApprovedCompleted
NCT00384410Phase 2UNKNOWN

Competing Products

20 competing products in Neuropathic Pain

See all competitors
ProductCompanyStageHype Score
CHF6467 activeComac MedicalPhase 1/2
33
LY3857210 + PlaceboEli LillyPhase 2
52
OK-101 0.05% + OK-101 0.1% + PlaceboOKYO PharmaPhase 2
44
YHD1119 + LyricaYuhanPhase 3
77
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
33
pregabalin sustained release tablet + pregabalin immediate release capsuleYuhanApproved
85
DS-5565 + placeboDaiichi SankyoPhase 3
77
Mirogabalin + PlaceboDaiichi SankyoPhase 3
77
DS-1971a + placebo + pregabalinDaiichi SankyoPhase 2
52
DS-5565Daiichi SankyoPhase 3
77
Placebo + MirogabalinDaiichi SankyoPhase 3
77
QutenzaAstellas PharmaPre-clinical
23
Qutenza exposureAstellas PharmaPre-clinical
23
Duloxetine + Pregabalin + PlaceboShionogiApproved
85
LY3016859 + PlaceboEli LillyPhase 2
52
LY3556050 + PlaceboEli LillyPhase 2
52
LY3526318 + PlaceboEli LillyPhase 2
52
LY4065967 + PlaceboEli LillyPhase 2
52
LY3848575 + PlaceboEli LillyPhase 2
52
ABT-639 + pregabalin + PlaceboAbbViePhase 2
52